Market Trends of Global Migraine Therapeutics Industry
This section covers the major market trends shaping the Migraine Therapeutics Market according to our research experts:
The Triptans Segment Is Expected to Grow at a Healthy CAGR Over the Forecast Period
Triptans are a newer class of drug that increases serotonin levels in the brain, reducing inflammation and constricting blood vessels, effectively ending a migraine. Triptans constrict blood vessels in the brain and block pain pathways. These ergotamines are more migraine-specific than previous ergotamines. Almotriptan (Axert), eletriptan (Relpax), frovatriptan (Frova), naratriptan (Amerge), rizatriptan (Maxalt, Maxalt-MLT), sumatriptan (Imitrex), sumatriptan and naproxen (Treximet), and zolmitriptan (Zomig) are some of the triptans available. Sumatriptan and naproxen sodium (Treximet), a single-tablet combination, are more effective than either medication alone in alleviating migraine symptoms.
Furthermore, as per the study titled "Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine" published in JAMA Network in October 2020, ditans and gepants were associated with less efficacy compared with triptans, whereas gepants were associated with fewer adverse events compared with triptans. Thus, due to the higher efficacy of the triptans, there is expected to be a rise in demand for them, thereby boosting the segment over the forecast period.
Moreover, the product launches and market approvals for drugs in the triptan class are also driving the growth of the market segment. For instance, in January 2020, Eli Lilly and Company launched the REYVOW (lasmiditan) C-V 50 mg and 100 mg tablets. It is an oral medication for the acute treatment of migraine with or without aura in adults.
Thus, owing to the aforementioned factors such as the higher efficacy of triptan and new product launches, the market segment is expected to boost the market over the forecast period.
North America is Expected to Hold a Significant Share Over the Forecast Period
North America is expected to dominate the overall market and is projected to maintain its dominance over the coming years. The high prevalence of migraine, the increasing adoption of novel therapeutics, and the large target population in the United States are the factors that contribute to the region's dominance.
According to the article titled "What is Migraine?" published in the JAMA Network in January 2022, in the United States, 17.1% of women and 5.6% of men reported having migraine symptoms. Thus, such a high prevalence is expected to boost the migraine therapeutics market in the United States.
Additionally, various strategic activities by key market players, such as product launch and approval, as well as mergers and acquisitions, will boost the market growth. For instance, in February 2020, Lundbeck received VYEPTI (eptinezumab-jjmr) approval by the United States Food and Drug Administration (FDA) for the preventive treatment of migraine in adults. Furthermore, in May 2021, Biohaven Pharmaceutical Holding Company Ltd. received United States Food and Drug Administration (FDA) approval for NURTEC ODT (rimegepant 75 mg) for the preventive treatment of migraine. NURTEC ODT is indicated for adult patients with episodic migraine, e.g., those who experience fewer than 15 headache days per month. Such approvals propel the growth of the studied market over the forecast period.
Thus, owing to the abovementioned factors, the North American region is expected to dominate the market over the forecast period.
